Akari Therapeutics, Plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AKTX research report →
Companywww.akaritx.com
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
- CEO
- Abizer Gaslightwala
- IPO
- 2014
- Employees
- 8
- HQ
- London, GB
Price Chart
Valuation
- Market Cap
- $3.06M
- P/E
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- -0.04
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -123.29%
- ROIC
- -130.49%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-17,298,000 · 12.60%
- EPS
- $-20800.00 · -32400.00%
- Op Income
- $-17,275,000
- FCF YoY
- 15.81%
Performance & Tape
- 52W High
- $56.80
- 52W Low
- $3.02
- 50D MA
- $5.55
- 200D MA
- $18.45
- Beta
- 0.65
- Avg Volume
- 34.90K
Get TickerSpark's AI analysis on AKTX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 16, 25 | Neal James R | buy | 3,093 |
| Dec 16, 25 | Neal James R | buy | 3,093 |
| Dec 16, 25 | Neal James R | buy | 2,473 |
| Dec 16, 25 | Neal James R | buy | 2,473 |
| Dec 16, 25 | Prudo-Chlebosz Raymond | buy | 618,658 |
| Dec 16, 25 | Prudo-Chlebosz Raymond | buy | 618,658 |
| Dec 16, 25 | Prudo-Chlebosz Raymond | buy | 386,661 |
| Dec 16, 25 | Prudo-Chlebosz Raymond | buy | 386,661 |
| Dec 16, 25 | Patel Sandip I | buy | 247,462 |
| Dec 16, 25 | Patel Sandip I | buy | 247,462 |
Our AKTX Coverage
We haven't published any research on AKTX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AKTX Report →